摘要:
Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.
摘要:
The administration of cannabinoid receptor agonists for inhibition of transient lower esophageal sphincter relaxations, gastroesophageal reflux disease and regurgitation is disclosed.
摘要:
Novel compounds of formula (I) wherein R1 represents hydrogen; R2 represents hydroxy, fluoro, or an oxo group; R3 represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates, and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid. The compounds are useful in therapy, especially for the treatment of reflux disease. The invention is also related to processes for their preparation, intermediates of said process and pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy
摘要翻译:新的式(I)化合物,其中R 1代表氢; R 2表示羟基,氟或氧代基; R 3表示氢; R 4表示氢; 和其药学上可接受的盐,溶剂合物及其立体异构体,但(3-氨基-2-羟丙基)亚磺酸的外消旋物除外。 该化合物可用于治疗,特别是用于治疗反流疾病。 本发明还涉及其制备方法,所述方法的中间体和含有所述治疗活性化合物的药物组合物和所述活性化合物在治疗中的用途
摘要:
The present invention is directed to the use of (3-Amino-2-fluoropropyl)phosphinic acid or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of non-erosive reflux disease (NERD).
摘要:
The present invention relates to the use of GABAB receptor agonists for the inhibition of transient lower esophageal sphincter relaxations, and for the treatment of gastro-esophageal reflux disease.
摘要:
In some aspects of the invention, a method for determining access to data stored within one or more databases is described. The method includes the aspects of receiving a user request from a user at an inference engine for access to the data, wherein the inference engine is in communication with a rules database, including one or more rules governing access rights to the data. Moreover, the method includes the aspects of creating a user credential based on the application of one or more of the rules to a identity information related to the user. Further, the method includes the aspects of comparing the created user credential and the user request at the one or more databases to determine whether the user meets the access rights for retrieving the data. Furthermore, the method includes aspects of determining an answer as to whether the access of the data is permitted or denied.
摘要:
Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts; solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.
摘要:
The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.